ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements with these filters
iSERA Lifesciences will not comply with Regulation 23(9) for the half year ended 30 September 2026. Its capital and net worth are below exemption thresholds.
iSERA Lifesciences Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.
iSERA Lifesciences gave notice of a board meeting on November 4, 2026 to consider standalone unaudited results for the quarter and half year ended September 30, 2026. The filing also notes the trading window closure from October 1, 2026.
iSERA Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Promoters and directors of iSERA Lifesciences acquired shares through a preferential offer valued at ₹113.98 Crore. This transaction changes the company's capital structure.
Promoter Pratap Dadasaheb Deshmukh acquired 86.13 lakh shares via preferential allotment. His stake in iSERA Lifesciences shifted to 55.07% following the company's capital restructuring.
iSERA Lifesciences Limited approved the allotment of 1,61,82,800 equity shares on a preferential basis. The allotment, priced at Rs. 48.20 per share, total Rs. 78.00 Crore.
iSERA Lifesciences Limited conducted its 34th Annual General Meeting on 29th September 2026, where shareholders adopted the audited financial statements and re-appointed a director.
iSERA Lifesciences Limited has submitted its Annual Report for the financial year 2025-26. The 34th Annual General Meeting is scheduled for September 29, 2026.
iSERA Lifesciences has scheduled its 34th Annual General Meeting for September 29, 2026, and appointed a scrutinizer to oversee the voting process for the event.
iSERA Lifesciences filed its Monitoring Agency Report for the Rights Issue proceeds utilization for the quarter ended June 30, 2026.
iSERA Lifesciences Ltd reported a net loss of ₹0.3 Cr for Q1 FY27.
iSERA Lifesciences Ltd scheduled a board meeting for August 7, 2026. The board will consider the unaudited financial results for the quarter ended June 30, 2026.
iSERA Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per SEBI regulations.
iSERA Lifesciences issued a corrigendum to its Postal Ballot notice. It clarifies preferential equity share allotments and post-issue capital percentages.
iSERA Lifesciences approved a name change from Covidh Technologies and adopted a new logo. The Board also addressed BSE advisory matters regarding regulatory non-compliance.
iSERA Lifesciences Limited released its postal ballot scrutinizer report. Shareholders approved resolutions including share capital increases and related party transactions with requisite majority support.
iSERA Lifesciences is exempt from SEBI related party disclosure requirements for March 2026. Its capital and net worth remain below mandatory reporting thresholds.
Covidh Technologies Ltd reported revenue from operations of ₹1.2 Cr and net profit of ₹0.5 Cr (+150.0% YoY) for Q4 FY26.
iSERA Lifesciences reported an audited annual net profit of ₹0.26 Crore for FY2026. The board also approved standalone results and noted a successful ₹8.08 Crore rights issue.
iSERA Lifesciences Limited issued a postal ballot notice seeking approval for several matters, including a ₹78 Crore acquisition of iSERA Biological Limited via share swap. Other items include increasing authorised share capital to ₹25 Crore and adopting new articles and memorandum of association. Remote e-voting runs from April 22 to May 21, 2026.
iSERA Lifesciences Limited approved the acquisition of a 100% stake in iSERA Biological Limited for ₹78 Crore via a 1:1 share swap. The transaction will be executed through a preferential allotment of 1,61,82,800 equity shares at ₹48.20 per share. Upon completion, iSERA Biological will become a wholly-owned subsidiary.
iSERA Lifesciences Limited approved the acquisition of 100% stake in iSERA Biological Limited for ₹78 Crore via a share swap. The board also approved increasing authorised share capital to ₹25 Crore and adopting a new Memorandum and Articles of Association. The acquisition will make iSERA Biological a wholly-owned subsidiary, creating strategic synergies in the pharmaceutical sector.
iSERA Lifesciences Limited has deferred its Board Meeting scheduled for April 20, 2026. The meeting was intended to consider a preferential issue of equity shares on a private placement basis. The deferment is due to additional time required for procedural and documentation formalities related to the proposed issuance.
iSERA Lifesciences Limited has scheduled a Board Meeting on April 20, 2026. The board will consider and approve a preferential issue of equity shares on a private placement basis. This move indicates the company's intent to raise capital for strategic purposes.
Covidh Technologies Limited has officially changed its name to iSERA Lifesciences Limited effective April 10, 2026. The Registrar of Companies, Pune, approved the change and the consequent alteration of the company's Memorandum and Articles of Association. This rebranding follows a special resolution passed by members at an EGM on April 2, 2026.
Covidh Technologies Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The Registrar and Share Transfer Agent, Skyline Financial Services, confirmed that no physical shares were received for dematerialisation during the quarter. This is a routine regulatory filing.
Covidh Technologies Limited successfully concluded its EGM, where shareholders approved a company name change to 'iSERA Lifesciences Limited'. Additionally, four director appointments, including two Executive Directors and two Non-Executive Directors, were passed with a 100% majority of votes polled. The meeting recorded a voter turnout of 18.25% of the total outstanding shares.